U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Application, And Segment Forecasts, 2023 - 2030

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, Large Molecule), By Application, And Segment Forecasts, 2023 - 2030

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Growth & Trends

The U.S. generic injectables pharmaceutical contract manufacturing market size is expected to reach USD 5.39 billion by 2030, according to a new report by Grand View Research, Inc. The U.S. market is expected to expand at a CAGR of 10.7% from 2023 to 2030. Key factors driving the growth of this market are the rising frequency of patent expirations for blockbuster drugs, streamlined regulatory pathways, low cost of generics, and increasing penetration of CDMOs in the generic injectables space.

The COVID-19 pandemic significantly impacted the supply chain market and its management, including the U.S. generic injectables pharmaceutical contract manufacturing sector. The conduction of clinical trials for new generic injectables has been modified or delayed due to pandemic-related safety concerns and restrictions, potentially impacting the development timeline. Furthermore, several pharmaceutical companies pivoted their production capacities to manufacture COVID-19 vaccines, significantly impacting the production timelines and capacity for other pharmaceuticals, including generic injectables.

The increasing number of patent expirations for biologic injectables is a key factor contributing to the growth of the generic injectables market in the country. For instance, as per the U.S. FDA, the blockbuster injectable drug Humira, developed by AbbVie Inc. that treats the symptoms of Crohn’s disease, arthritis, plaque psoriasis, and Ankylosing Spondylitis, has lost its patent in 2023. This expiration has paved the way for introducing its generic counterpart, adalimumab. The rising demand for generics owing to their cost-effectiveness is another significant factor contributing to the growth of the U.S. market for generic injectables pharmaceutical contract manufacturing.

U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Report Highlights

• Based on molecule type, the U.S. market is segmented into small molecule and large molecule, with the large molecule segment accounting for the higher revenue share of 61.3% in 2022. This is majorly due to the increasing launch rate of biosimilars across the U.S.
• The neurology segment is anticipated to advance at the fastest CAGR of 11.3% during the forecast period. This is due to the growing prevalence of neurological conditions requiring innovative and cost-effective therapeutics, thereby boosting demand for generic injectables to treat several types of disorders
• The U.S. market is anticipated to witness a lucrative growth rate of 10.7% during the analysis timeframe due to the significant presence of contract manufacturers and a notable increase in the outsourcing of pharmaceutical and biopharmaceutical products in the U.S. market in recent years

Please note The report will be delivered in 2-3 business days upon order notification.